Mitral surgery: which clinical factors truly dictate the prognosis?

Context and challenges of minimally invasive mitral surgery

The treatment of mitral valve disease is evolving in a context of significant population aging, where the decision-making between conservative, transcatheter, and surgical options becomes crucial. While mitral valve repair remains the gold standard for severe mitral regurgitation (MR), the choice of technique depends closely on the etiology — primary or secondary — as well as left ventricular remodeling. In this landscape, minimally invasive mitral valve surgery (MIMVS) is establishing itself as a preferred alternative to conventional median sternotomy, aiming to reduce surgical trauma and optimize postoperative recovery for fragile patients.

This systematic review, with a PubMed literature search extending until January 31, 2025, and covering the 2018-2024 period, aims to identify the comorbidities and anatomical configurations influencing MIMVS outcomes. The study specifically evaluates early complications, such as in-hospital mortality and repair failures, as well as late outcomes including recurrence of regurgitation. The central hypothesis is based on the fact that the patient's preoperative profile (NYHA class, ventricular function, pulmonary hypertension) and valvular characteristics directly impact operative performance indicators — notably cardiopulmonary bypass and clamping times — as well as the duration of stay in intensive care.

Methodology of the systematic review

This systematic review was conducted in accordance with PRISMA guidelines. The authors extracted data from PubMed for the 2018-2024 period, including randomized trials, observational studies, and case-control studies focusing on minimally invasive mitral valve surgery (MIMVS).

• Population: The analysis covers 164 articles totaling 222,947 patients (96,682 women and 126,265 men).
• Extracted preoperative data: NYHA class, BMI, body surface area (BSA), atrial fibrillation (AF), pulmonary artery pressure, ejection fraction (EF) and severity of valvular regurgitation.
• Analyzed comorbidities: Chronic kidney disease (CKD), arterial hypertension, COPD, diabetes, coronary artery disease, history of stroke and hyperlipidemia.
• Paramètres périopératoires : Durée de circulation extracorporelle (CEC) et temps de clampage aortique (AoX).
• Postoperative outcome criteria: Repair failure, 30-day hospital mortality, reinterventions (redo), recurrent regurgitations, neurological events (stroke/TIA) and vascular or haemorrhagic complications.

Echocardiographic data (LVEF, left atrial dimensions, mean pressures) were systematically compiled to evaluate the impact of anatomical parameters on clinical outcomes. The conversion rate to sternotomy was retained as a major safety criterion.

Literature analysis and data selection

Out of a total of 2,867 articles initially identified, rigorous selection resulted in 164 relevant publications for the final analysis (94 from PubMed and 70 from secondary literature). This systematic review compiles data from 222,947 patients, covering a publication period of 23 years, although the analysis focused on the last six years (2018-2024).

Thematic focus and clinical profiles

The synthesis of the 164 articles reveals a heterogeneity of research objectives, ranging from postoperative quality of life to the comparison between robotic and non-robotic surgery. Two major axes emerge from the selected publications:

• Barlow's disease: 8 publications focused specifically on this pathology.
• MIMVS vs Sternotomy: 19 studies directly compared minimally invasive mitral surgery to conventional sternotomy.

Regarding hemodynamic parameters, the authors specify that for the analysis of severely impaired left ventricular ejection fractions (LVEF), a floor threshold of 35% was uniformly applied to all patients concerned. The populations studied include mitral pathologies of primary and secondary etiologies, with particular attention paid to comorbidities influencing 30-day mortality and the failure rate of repair requiring valve replacement.

A major shift for minimally invasive mitral surgery

This systematic review, compiling data from 222,947 patients across 164 recent studies (2018-2024), marks a turning point: minimally invasive mitral valve surgery (MIMVS) is no longer a technical niche but a reproducible alternative to median sternotomy. The analysis highlights that the reduction in surgical trauma directly impacts postoperative recovery and quality of life, particularly in elderly patients or those with cardiac comorbidities. The study validates MIMVS as a standard of care capable of meeting the challenges of increased life expectancy.

Methodological limits and gray areas

The weak point of this synthesis lies in the heterogeneity of the reported data. The authors note that not all publications provide all pre, peri, and postoperative variables. A significant bias should be noted: for the statistical analysis, patients with a very low LVEF were arbitrarily fixed at 35%. This simplification obscures the precision of the results for end-stage heart failure. Furthermore, although 164 articles are included, the disparity between robotic and non-robotic studies complicates the overall interpretation of late complications.

Implications for patient selection

Les résultats confirment que le succès de la MIMVS repose sur un screening préopératoire rigoureux. L'imagerie par scanner (CTA) est indispensable pour évaluer l'aorte et les accès iliaques, tandis que l'échographie 3D reste le juge de paix pour quantifier l'orifice régurgitant (EROA ≥ 20 mm² étant un prédicteur de mortalité). Pour le praticien, la question n'est plus de savoir si la MIMVS est efficace, mais d'identifier précisément les profils (calcifications annulaires massives ou anatomies thoraciques défavorables) où le bénéfice du mini-invasif s'efface devant la sécurité de la sternotomie.

Study summary

This systematic review evaluates the impact of comorbidities on the outcomes of minimally invasive mitral valve surgery (MIMVS). It identifies critical clinical thresholds: an effective regurgitant orifice area (EROA) ≥ 20 mm², a left atrial diameter ≥ 55 mm, and a left ventricular end-systolic diameter (LVESD) ≥ 40 mm, all of which are correlated with increased mortality and an elevated risk of postoperative complications.

In concrete terms, for the practitioner:

• Do not wait for decompensation: Ideally, intervene before the LVESD reaches 45 mm or the LVEF drops below 60%, thresholds associated with significantly less favorable postoperative outcomes.
• Prioritize repair: Mitral valve repair remains the gold standard; systematically prioritize it over prosthetic replacement to ensure better survival and long-lasting results.
• Secure through the minimally invasive approach: For your fragile or elderly patients, MIMVS constitutes a robust alternative that reduces surgical trauma and accelerates functional rehabilitation without compromising safety.

Technical lexicon of the study

EROA (Effective Regurgitant Orifice Area): Effective regurgitant orifice area. A value ≥20 mm² is correlated with high mortality according to the data synthesized by this review.

LVESD (Left Ventricular End-Systolic Diameter): Left ventricular end-systolic diameter. Critical thresholds of ≥40 mm and ≥45 mm are reported as markers of ventricular remodeling impairing the prognosis.

MIMVS (Minimally Invasive Mitral Valve Surgery): Minimally invasive mitral surgery. This approach, including robotic techniques, is evaluated as a safe alternative to sternotomy to reduce operative trauma.

RHD (Rheumatic Heart Disease): Rheumatic Heart Disease. Identified as a major cause of primary mitral valve pathology, particularly prevalent in developing countries.

LA dimension (Left Atrial dimension): Left atrial dimension. The review cites a threshold of ≥55 mm as an atrial remodeling parameter to be considered before the procedure.

AoX (Aortic Cross-Clamp): Aortic cross-clamp time. Fundamental perioperative variable analyzed to compare the feasibility and safety of different surgical techniques.

CPB (Cardiopulmonary Bypass): Duration of cardiopulmonary bypass. Key parameter extracted from studies to evaluate the impact of minimally invasive procedures on patient recovery.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always verifying with the original source article. Delynov disclaims all responsibility regarding the use of this information. This document is not intended for patients or the general public.